An Overview of Endometriosis and Potential Pharmacogenetic Targets

Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care.

Authors

Institutions

Publication Details

Journal
Pharmaceutical Research
Published
2026-02-24
DOI
https://doi.org/10.1007/s11095-026-04049-9
Primary Topic
Endometriosis Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An Overview of Endometriosis and Potential Pharmacogenetic Targets

Noelia Pérez-Gómez, Dora Koller, María Ángeles Martínez-Zamora, Francisco Abad-Santos et al.
Pharmaceutical Research
Endometriosis Research and Treatment
article

An Overview of Endometriosis and Potential Pharmacogenetic Targets

Noelia Pérez-Gómez, Dora Koller, María Ángeles Martínez-Zamora, Francisco Abad-Santos, Jesús Novalbos, Francisco Carmona
article en

Abstract

Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care.

Pharmaceutical Research
Yale University (US), Hospital Clínic de Barcelona (ES), Hospital Universitario de Burgos (ES), Hospital Universitario de La Princesa (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Universidad de Burgos (ES), Universidad Autónoma de Madrid (ES), Universitat de Barcelona (ES)
Good health and well-being
Openalex Percentile: Top 39%
Endometriosis Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.